Lancet Regional Health-Europe最新文献

{"title":"Charting a healthier tomorrow for Europe's children and adolescents","authors":"Hans Henri P. Kluge , Regina De Dominicis","doi":"10.1016/j.lanepe.2025.101548","DOIUrl":"10.1016/j.lanepe.2025.101548","url":null,"abstract":"","PeriodicalId":53223,"journal":{"name":"Lancet Regional Health-Europe","volume":"59 ","pages":"Article 101548"},"PeriodicalIF":13.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145623529","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sexually transmitted infection testing and key outcomes following implementation of online postal self-sampling into sexual health services in England: a retrospective observational study of routinely collected service-level healthcare data","authors":"Jo Gibbs , Oliver Stirrup , Anna Tostevin , Alison Howarth , Claire Dewsnap , Jonathan D.C. Ross , Andy Williams , Vicky Tittle , Sara Day , Jack Brown , David Crundwell , Louise J. Jackson , Catherine H. Mercer , Jessica Sheringham , Ann Sullivan , Andrew J. Winter , Geoff Wong , Andrew Copas , Fiona Burns","doi":"10.1016/j.lanepe.2025.101541","DOIUrl":"10.1016/j.lanepe.2025.101541","url":null,"abstract":"<div><h3>Background</h3><div>A shift to online postal self-sampling (OPSS) for sexually transmitted infections (STIs) in high-income settings has occurred. We evaluate whether introduction of OPSS in England is associated with changes in testing activity and if this differs by population characteristics.</div></div><div><h3>Methods</h3><div>A retrospective study of sexual health (online and clinic-based) service-level data, across three case study areas (CSAs) that implemented OPSS at different times, using different models, and whose populations have different socio-demographic profiles, between 01/01/2015 and 31/12/2022 (from 01/08/2014 in CSA1 to ensure 12 months pre-OPSS). The primary outcome was chlamydia/gonorrhoea and HIV testing activity. We evaluated change over time using selected calendar years, with total activity following introduction of OPSS (2019 and 2022) compared to pre-OPSS periods (CSA1, 2014–2015, CSA2 2017, CSA3 2019), and whether outcome changes differed by socio-demographic characteristics.</div></div><div><h3>Findings</h3><div>In all CSAs chlamydia/gonorrhoea and HIV testing activity increased following introduction of OPSS with incidence rate ratios (IRR) for chlamydia/gonorrhoea testing in 2022 compared to pre-OPSS baseline ranging from 2.1 (95% CI 2.1–2.2) in CSA1 to 2.5 (95% CI 2.4–2.5) in CSA3, and for HIV testing from 1.5 (95% CI 1.5–1.5) in CSA1 to 2.8 (95% CI 2.8–2.8) in CSA2. Differences existed across all demographic characteristics in the relative change in testing incidence (all P < 0.0001 for chlamydia/gonorrhoea). Higher testing activity via OPSS was seen among men who have sex with men (MSM), particularly in CSAs1-2 for chlamydia/gonorrhoea (IRR2.9 (95% CI 2.8–3.1) and 3.6 (95% CI 3.5–3.7) in MSM compared to 1.7 (95% CI 1.7–1.8)and 1.8 (95% CI 1.8–1.8) in men who have sex exclusively with women (MSEW) for 2022 <em>vs</em> pre-OPSS). In CSA3, the largest relative increase occurred in women (IRR 3.2 (95% CI 3.1–3.3), compared to IRR 1.9 (95% CI 1.8–1.9) in MSEW). The most deprived areas had the lowest relative increase in chlamydia/gonorrhoea testing uptake (1.9–2.1 for CSA1-3).</div></div><div><h3>Interpretation</h3><div>Despite a reduction in clinic-based testing linked to COVID-19, the introduction of OPSS has been associated with increases in overall testing activity. OPSS uptake was lower among populations with greater potential for unmet need, such as individuals living in more deprived areas. Although OPSS is available to all people living within the commissioned areas, in practice not all individuals with a need for STI testing are aware of it or have the confidence and ability to access it. Differences across all socio-demographic characteristics in the relative change in testing could inadvertently increase existing inequalities in access to care and it is important to offer choice of mode of testing for service users.</div></div><div><h3>Funding</h3><div><span>National Institute for Health and C","PeriodicalId":53223,"journal":{"name":"Lancet Regional Health-Europe","volume":"61 ","pages":"Article 101541"},"PeriodicalIF":13.0,"publicationDate":"2025-11-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145624595","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Validation of an algorithm for selection of SGLT2 and DPP4 inhibitor therapies in people with type 2 diabetes across major UK ethnicity groups: a retrospective cohort study","authors":"Laura M. Güdemann ,&nbsp;Katherine G. Young ,&nbsp;Pedro Cardoso ,&nbsp;Bilal A. Mateen ,&nbsp;Rury R. Holman ,&nbsp;Naveed Sattar ,&nbsp;Ewan R. Pearson ,&nbsp;Andrew T. Hattersley ,&nbsp;Angus G. Jones ,&nbsp;Beverley M. Shields ,&nbsp;John M. Dennis","doi":"10.1016/j.lanepe.2025.101547","DOIUrl":"10.1016/j.lanepe.2025.101547","url":null,"abstract":"<div><h3>Background</h3><div>Routine clinical features of individual patients can potentially be used to guide selection of type 2 diabetes treatments. We aimed to evaluate a recently proposed treatment selection model predicting differences in glycaemic responses to SGLT2-inhibitors and DPP4-inhibitors across major UK ethnicity groups.</div></div><div><h3>Methods</h3><div>We externally validated the SGLT2i-DPP4i model in UK primary care cohort (CPRD Aurum, 2013–2020) independent of the original model development cohort. Non-insulin treated individuals with type 2 diabetes were identified and categorised by major UK self-reported ethnicity groups: White, Black, South Asian and Mixed/Other. For each ethnicity group, we applied a closed testing procedure to assess whether model recalibration was required. After model updates, we assessed the calibration accuracy of predicted differences in glycaemic response (6-month change in HbA1c) between SGLT2i and DPP4i for each ethnicity group.</div></div><div><h3>Findings</h3><div>SGLT2i (n = 57,749) and DPP4i (n = 87,807) initiations were identified amongst people of White (n = 114,287; 78.5%), Black (n = 6663; 4.6%), South Asian (n = 20,969; 14.4%) and Mixed/Other (n = 3637; 2.5%) ethnicities. Minor model adjustment was required to adjust for greater observed than predicted glycaemic responses to DPP4i (White—1.6 mmol/mol; Black—3.0 mmol/mol; South Asian—2.6 mmol/mol; Mixed/Other—2.6 mmol/mol). SGLT2i predictions did not require adjustment for non-White ethnicity groups. After model updates, average predicted HbA1c reduction was 3.7 mmol/mol (95% CI 3.5–3.9) greater with SGLT2i than DPP4i for those of White ethnicity; this was greater than for those of South Asian (2.1 mmol/mol (95% CI 1.6–2.6)), Black (0.6 mmol/mol (95% CI 0.5–1.7)) and Mixed/Other (2.6 mmol/mol (95% CI 1.4–3.8)) ethnicity groups. For all ethnicity groups, predicted differential glycaemic treatment effects were well calibrated.</div></div><div><h3>Interpretation</h3><div>Our model for selection of SGLT2-inhibitor and DPP4-inhibitor therapies was accurate for all major self-reported ethnicity groups in a UK primary care cohort. Simple recalibration is beneficial to optimise performance and this is recommended prior to deployment of the model in new populations and settings.</div></div><div><h3>Funding</h3><div><span>UK Medical Research Council</span>, <span>National Institute for Health and Care Research Exeter Biomedical Research Centre</span>, and <span>EFSD</span>/Novo Nordisk.</div></div>","PeriodicalId":53223,"journal":{"name":"Lancet Regional Health-Europe","volume":"61 ","pages":"Article 101547"},"PeriodicalIF":13.0,"publicationDate":"2025-11-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145624594","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Promising measures for minimising e-cigarette youth uptake in countries with a significant e-cigarette market","authors":"Rosemary Hiscock","doi":"10.1016/j.lanepe.2025.101545","DOIUrl":"10.1016/j.lanepe.2025.101545","url":null,"abstract":"","PeriodicalId":53223,"journal":{"name":"Lancet Regional Health-Europe","volume":"60 ","pages":"Article 101545"},"PeriodicalIF":13.0,"publicationDate":"2025-11-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145623614","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pediatric thyroid cancer in Europe: time to act and rethink care","authors":"Sarah C. Clement ,&nbsp;Hanneke M. van Santen","doi":"10.1016/j.lanepe.2025.101551","DOIUrl":"10.1016/j.lanepe.2025.101551","url":null,"abstract":"","PeriodicalId":53223,"journal":{"name":"Lancet Regional Health-Europe","volume":"60 ","pages":"Article 101551"},"PeriodicalIF":13.0,"publicationDate":"2025-11-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145623615","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The burden of dietary risk factors in the Nordic and Baltic countries: a systematic analysis for the Global Burden of Disease Study 2023","authors":"","doi":"10.1016/j.lanepe.2025.101543","DOIUrl":"10.1016/j.lanepe.2025.101543","url":null,"abstract":"<div><h3>Background</h3><div>Detailed knowledge about the disease burden from unhealthy diet in Nordic and Baltic countries is lacking. This study quantifies and compares deaths and disability-adjusted life-years (DALYs) from dietary risks in these countries.</div></div><div><h3>Methods</h3><div>Data from the Global Burden of Disease study 2023 (GBD 2023) was used. Attributable disease burden from 15 dietary risks was analysed using the comparative risk assessment framework. Steps included: (1) estimating dietary intake; (2) assessing relative risks of dietary factors on disease endpoints; (3) determining theoretical minimum risk exposure levels (TMREL); and (4) estimating dietary risk-attributable disease burden as numbers and age-standardised rates (ASR) of deaths and DALYs.</div></div><div><h3>Findings</h3><div>Across the Nordic and Baltic countries (total population = 34,064,020), dietary risks resulted in 38,450 attributed deaths (95% uncertainty interval 10,749–59,386) and 735,284 DALYs (242,417–1,06,638) in 2023. Leading dietary risks included high intake of processed meat and low intake of fruits and whole grains. Dietary risks accounted for 24.9% of cardiovascular disease burden (5.0–37.6), 29.6% of diabetes and kidney disease burden (18.6–40.0), and 7.8% of neoplasm burden (2.9–12.1), with higher burden in the Baltic countries and Greenland than in the Nordic countries.</div></div><div><h3>Interpretation</h3><div>A substantial disease burden can be attributed to dietary risks in the Nordic and Baltic countries. Knowledge about the impact from unhealthy diet can inform targeted public health policies.</div></div><div><h3>Funding</h3><div><span>Gates Foundation and Norwegian Institute of Public Health</span>.</div></div>","PeriodicalId":53223,"journal":{"name":"Lancet Regional Health-Europe","volume":"61 ","pages":"Article 101543"},"PeriodicalIF":13.0,"publicationDate":"2025-11-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145624593","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"COVID-19 public health and social measures (PHSM) and early childhood developmental concerns in Scotland: an interrupted time series analysis","authors":"Iain Hardie ,&nbsp;Louise Marryat ,&nbsp;Aja Murray ,&nbsp;Josiah King ,&nbsp;Kenneth Okelo ,&nbsp;Lynda Fenton ,&nbsp;Abigail K. Stevely ,&nbsp;James P. Boardman ,&nbsp;Michael V. Lombardo ,&nbsp;Sarah J. Stock ,&nbsp;Rachael Wood ,&nbsp;Bonnie Auyeung","doi":"10.1016/j.lanepe.2025.101525","DOIUrl":"10.1016/j.lanepe.2025.101525","url":null,"abstract":"<div><h3>Background</h3><div>COVID-19 public health and social measures (PHSM) may have affected children's development, for example by reducing their interaction with others. We examined associations between PHSM and developmental concerns among young children in Scotland.</div></div><div><h3>Methods</h3><div>We utilised data from routine 13–15 month and 27–30 month child health reviews, covering all children in Scotland who took part in reviews between January 2019 and August 2023 and had full developmental data. Interrupted time-series analysis assessed slope changes in the weekly proportion of children with health visitor-identified developmental concerns following the March 2020 introduction of, and August 2021 removal of, PHSM. Outcomes were any 13–15 month and 27–30 month developmental concerns, and domain-specific concerns regarding speech-language-communication, problem solving, gross motor, personal-social, emotional-behavioural and fine motor development.</div></div><div><h3>Findings</h3><div>Weekly proportions were based on 257,532 children, covering 13–15 month review records for 186,265 children (95,506 [51.3%] male and 90,756 [48.7%] female) and 27–30 month review records for 186,766 children (95,209 [51.0%] male and 91,557 [49.0%] female). The March 2020 PHSM introduction was associated with a slope change increase in the proportion of children with any developmental concerns (+0.091 percentage points per week [95% CI: 0.065, 0.116] at 13–15 months and +0.076 percentage points per week [95% CI: 0.048, 0.104] at 27–30 months. The August 2021 PHSM removal was associated with a slope change decrease in the proportion of children with any developmental concerns at 27–30 months (−0.067 percentage points per week [95% CI: −0.088, −0.046]), but not 13–15 months, in the main analysis. Results were broadly consistent across developmental domains.</div></div><div><h3>Interpretation</h3><div>COVID-19 PHSM were associated with increased developmental concerns among young children in Scotland. While leveraging interrupted time-series analysis yields findings consistent with a causal impact of PHSM, the influence of potential time-varying confounders cannot be ruled out.</div></div><div><h3>Funding</h3><div>Economic and Social Research Council.</div></div>","PeriodicalId":53223,"journal":{"name":"Lancet Regional Health-Europe","volume":"60 ","pages":"Article 101525"},"PeriodicalIF":13.0,"publicationDate":"2025-11-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145790203","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The NITAG debate in Italy: an opportunity for prevention","authors":"Massimo Agosti","doi":"10.1016/j.lanepe.2025.101487","DOIUrl":"10.1016/j.lanepe.2025.101487","url":null,"abstract":"","PeriodicalId":53223,"journal":{"name":"Lancet Regional Health-Europe","volume":"59 ","pages":"Article 101487"},"PeriodicalIF":13.0,"publicationDate":"2025-11-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145579110","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Management and Outcomes of Perioperative Care of People with Diabetes across Europe (MOPED): a prospective, observational study","authors":"Donal J. Buggy ,&nbsp;Malachy O. Columb ,&nbsp;Jeroen Hermanides ,&nbsp;Markus W. Hollmann ,&nbsp;Mark Coburn ,&nbsp;Alexander Zarbock ,&nbsp;MOPED Investigators","doi":"10.1016/j.lanepe.2025.101535","DOIUrl":"10.1016/j.lanepe.2025.101535","url":null,"abstract":"<div><h3>Background</h3><div>The prevalence of people with Diabetes Mellitus (DM) presenting for surgery is increasing. Guidelines on perioperative management are based on expert opinion with variability of practice likely. Our objective was to document perioperative management and 30-day outcomes of people with DM across Europe.</div></div><div><h3>Methods</h3><div>This was a prospective, observational study involving 89 hospitals across 21 European countries, ranging from district general to tertiary referral centres. Between January 2021 and February 2024, 6126 people with confirmed DM (any type except gestational) receiving surgery of any kind requiring anaesthesia were followed for 30 days. Centres were self-selected by anaesthesiology clinicians working there, who enrolled consecutive people with DM to a locally determined target number. There was 5936 (97%) 30-day follow-up completion. The primary outcome was Days at Home at 30 Days (DAH-30). Secondary outcomes included descriptive characteristics of perioperative management, dysglycaemia and incidence of postoperative complications.</div></div><div><h3>Findings</h3><div>There was significant variation between countries in perioperative DM management and 30-day outcomes, and variance in DAH-30 (median [range]) 26 [23–30] days, P = 0.0001). The proportion of people with DM with increased HbA1c (&gt;69 mmol mol) was higher in T1DM compared with T2DM (n = 51, 18% vs n = 388, 7%; difference 11%, 95% CI 6–17; P = 0.002). In univariate analysis, there was an association between patients with lower HbA1c &lt; 53 mmol mol⁻¹ median (25–75% range) DAH-30 = 27 days (23–29), contrasting with higher HbA1c &gt; 69 mmol mol, median DAH-30 = 25 days (20–28); difference 2.0, 95% CI 1.3–2.7; P &lt; 0.0001). This association was upheld in multivariable analysis only for patients with little blood loss.</div></div><div><h3>Interpretation</h3><div>There is a need to harmonise international practice to reduce variability in perioperative diabetes management and 30-day outcome.</div></div><div><h3>Funding</h3><div>The <span>European Society of Anaesthesiology and Intensive Care</span> (ESA-IC) funded administrative staff throughout the conduct of the study. The <span>College of Anaesthesiologists of Ireland</span> (CAI) and <span>British Journal of Anaesthesia</span> (BJA) partially contributed to data collection in Ireland and UK.</div></div>","PeriodicalId":53223,"journal":{"name":"Lancet Regional Health-Europe","volume":"61 ","pages":"Article 101535"},"PeriodicalIF":13.0,"publicationDate":"2025-11-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145580502","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hospital mortality, withdrawal of life-sustaining therapy decisions and early secondary brain insults for critically ill traumatic brain injury patients in England, Wales and Northern Ireland (2009–2024): an observational cohort study","authors":"Xavier Chapalain ,&nbsp;Olivier Huet ,&nbsp;Kathryn M. Rowan ,&nbsp;Paul R. Mouncey ,&nbsp;Olivier Langeron ,&nbsp;David K. Menon ,&nbsp;David A. Harrison","doi":"10.1016/j.lanepe.2025.101538","DOIUrl":"10.1016/j.lanepe.2025.101538","url":null,"abstract":"<div><h3>Background</h3><div>Recent epidemiological studies reported conflicting results regarding mortality trends for traumatic brain injury (TBI) patients. Mortality trends for the critically ill TBI population, and their drivers of changes, remains understudied. Particularly, withdrawal of life-sustaining therapy (WLST) decisions were rarely evaluated concurrently. In this study, we aimed to describe hospital mortality and WLST trends over the past 15 years in England, Wales and Northern Ireland for TBI patients admitted to an intensive care unit (ICU).</div></div><div><h3>Methods</h3><div>Observational cohort study, involving 235 adult ICUs participating in the Intensive Care National Audit &amp; Research Centre (ICNARC) Case Mix Programme (CMP). From April 1, 2009 to March 31, 2024, all TBI patients were included. Comparator cohorts consisted of patients with trauma, sepsis, and vascular brain injury recorded in the CMP. The primary outcome was hospital mortality. The secondary outcome was the incidence of WLST decisions. We also examined the proportion of patients experiencing predefined early secondary brain insults.</div></div><div><h3>Findings</h3><div>Of the 2,324,961 ICU admissions, we identified 45,684 unique TBI patients. Over the study period, hospital mortality for TBI patients increased from 25.6% (1021/3988) to 35.0% (1306/3727). The proportion of WLST decisions rose from 7.5% (301/4024) to 19.7% (759/3850). After adjustment for main confounders, multivariable analyses confirmed these trends. No similar trends were observed among the comparator cohorts. TBI patients were exposed to hypotension, hypocapnia, hypercapnia and hyperglycaemia in 49.8% (22,559/45,298), 29.9% (12,356/41,262), 33.6% (13,869/41,262) and 29.2% (12,127/41,505) of cases, respectively. Half of patients (50.3%, 20,747/41,265) were exposed to hypoxaemia, and this proportion increased markedly from 36.9% (1359/3684) to 61.2% (2186/3572) over time.</div></div><div><h3>Interpretation</h3><div>For critically ill TBI patients, hospital mortality and WLST decisions rates increased over time. These findings raise important questions regarding the processes and ethical frameworks underpinning WLST decisions.</div></div><div><h3>Funding</h3><div><span>UKRI</span>, <span>NIHR</span>, <span>UK Ministry of Defence</span>, <span>Alzheimer’s Research</span> UK, <span>French Society of Anaesthesiology and Critical Care</span>, <span>Gueules Cassées Foundation</span>, <span>INNOVEO donation fund</span>.</div></div>","PeriodicalId":53223,"journal":{"name":"Lancet Regional Health-Europe","volume":"61 ","pages":"Article 101538"},"PeriodicalIF":13.0,"publicationDate":"2025-11-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145580501","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}